Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03823443 · ClinicalTrials.gov registry record
COPD Exacerbation Blood and Urine Biomarkers Study
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 7
- Enrollment target
NCT03823443 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 7 participants.
The verdict
NCT03823443 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be assessed against change in lung function as measured by pulmonary function testing.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-06-07 |
| Est. Completion | 2021-01-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03823443
The ClinicalTrials.gov registry entry for NCT03823443 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03823443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03823443 about?
NCT03823443 is a clinical study titled "COPD Exacerbation Blood and Urine Biomarkers Study". This will be a prospective study examining serum levels of MMP-13 and alpha-1 antitrypsin as well as other biomarkers as well as urine biomarkers of smoking status and collagen degradation in the COPD patient population. Serum and urine biomarkers at baseline and after COPD exacerbations will be ass...
What is the current status of trial NCT03823443?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2018-06-07. Estimated completion is 2021-01-08.
Who is sponsoring clinical trial NCT03823443?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.